R7 (drug)

R7 (drug)
Clinical data
Routes of
administration		 Oral
Legal status

R7 is a prodrug of 7,8-dihydroxyflavone (7,8-DHF) with significantly improved potency and pharmacokinetics (namely oral bioavailability) that is currently in preclinical development for the treatment of Alzheimer's disease.[1] As a prodrug of 7,8-DHF, R7 is a selective agonist of TrkB, the main receptor of brain-derived neurotrophic factor (BDNF).[1] 7,8-DHF shows robust efficacy in a variety of animal models of Alzheimer's disease as well as other conditions, making R7 a highly promising potential therapeutic agent.[1] The chemical structure of the compound has yet to be published.[1]

See also

References



This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.